NuPathe Inc. (PATH) Files $86.25M IPO
Tweet Send to a FriendGet Alerts PATH Hot Sheet
Trade PATH Now!
NuPathe, Inc. (Nasdaq: PATH) filed a registration statement with the U.S. Securities and Exchange Commission today for an Initial Public Offering of its shares. The proposed maximum aggregate offering price is $86.25 million. The company plans to list on the Nasdaq Global Market under the ticker "PATH."
The offering is being made through Leerink Swann, Lazard Capital Markets, Thomas Weisel Partners, and Needham & Company.
NuPathe is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders.
The offering is being made through Leerink Swann, Lazard Capital Markets, Thomas Weisel Partners, and Needham & Company.
NuPathe is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders.
You May Also Be Interested In
Create E-mail Alert Related Categories
IPOsRelated Entities
Needham & Company, Lazard, Thomas Weisel Partners Group
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
